Lilly's Lepodisiran Reduces Lipoprotein(a) Levels By Nearly 94% In Phase 2 Heart Disease Trial
31/3 03:33
(RTTNews) - Eli Lilly and Co.'s (LLY) Phase 2 trial results revealed that lepodisiran significantly lowered lipoprotein(a) levels, a genetically inherited heart disease risk factor. At the highest tested dose, the drug achieved an impressive reduction of nearly 94% from baseline...